| Learning Objectives |
Goals |
|
Teaching Methods |
|
|
Evaluation Method |
|
|
| |
To aquire: |
Textbook reading |
Lecture |
Clinical |
Test |
Faculty eval |
360 Evaluation |
|
| Knowlwedge base and clinical skills |
|
|
|
|
|
|
|
|
| General physiology and diagnosis |
|
|
|
|
|
|
|
|
| Atherosclerosis |
|
|
|
|
|
|
|
|
| pathogenesis |
Understand the disease process and pathology of atherosclerosis |
Topol: Chapter 19 |
|
|
V |
|
|
|
| preventive coronary therapy |
Undertsand the science and methods for preventing progression of atherosclerosis |
Topol: Chapter 6 |
|
V |
V |
|
|
|
| General coronary physiology |
Understanging of coronary vasomotion and transport, from the epicardial arties to the microcirculation |
|
R Bache, M.D. |
|
V |
V |
|
|
| Clinical coronary physiology |
Understanding of the application of coronary physiology to patients with coronary diseaseand the impact of intervention |
Kern:Chapter 10 |
|
V |
V |
V |
|
|
| FFR |
|
|
R. Wilson, M.D. |
V |
V |
|
|
|
| CFR |
|
|
R. Wilson, M.D. |
V |
V |
|
|
|
| coronary vasodilators |
|
|
R. Wilson, M.D. |
V |
V |
|
|
|
| coronary vasospasm and PCI |
|
|
|
V |
V |
|
|
|
| Valvular heart disease |
Understanding of normal valvular anatomy and pathology. |
|
|
|
V |
V |
|
|
| Valvular stenosis morphology |
Understanding the interaction of valve morphology and successful valve dilation, including selction of patients for treatment |
Otto: Chapters 7 |
Pedersen (Aortic); Baran (Mitral, PV) |
V |
V |
V |
|
|
| Valvular stenosis physiology |
Ability to quatitatively assess of valvular stenosis before and after intervention |
|
Pedersen (Aortic); Baran (Mitral, PV) |
V |
V |
V |
|
|
| Congenital heart disease |
General understanding of congenital heart disease anatomy and physiology amenable to percutaneous intervention |
Web module |
Das Lecture |
V |
V |
V |
|
|
| ASD/PFO |
Understanding ASD/PFO anatomy and assessment fo the size of the defect |
Kern: Chapter 15 Topol: Chapter 45 |
Das Lecture |
|
V |
V |
|
|
| Anatomy |
|
|
|
|
V |
V |
|
|
| Physiology and paradoxical embolism |
Understanding the hysiology and incidence of paradoxical embolism |
|
|
|
V |
V |
|
|
| VSD |
|
|
Bass Lecture |
V |
|
|
|
|
| Post MI/congenital anatomy |
|
|
|
|
V |
|
|
|
| Physiology |
|
|
|
|
V |
|
|
|
| Cardiac and coronary imaging |
|
|
|
|
|
|
|
|
| Radiation physics and safety |
Knowledge of radiation physics to allow optimal imaging and minimal exposure to the patient and staff |
|
Alan Berger, M.D. |
V |
V |
|
|
|
| Optimal coronary angiography for PCI |
Skill in selecting optimal angigraphic views to assess lesion morphology and suitability for PCI |
Kern: Chapter 3 |
Carl White, M.D. |
V |
V |
|
|
|
| Coronary lesion assessment |
Knowledge of how to apply coronary physiology to clinical problem solving |
|
|
|
|
|
|
|
| Physiologic |
|
Kern: Chapter 10 |
|
V |
V |
|
|
|
| FFR and CFR |
|
|
R. Wilson, M.D. |
V |
V |
|
|
|
| Clinical prediction of FFR/CFR |
|
|
R. Wilson, M.D. |
V |
V |
|
|
|
| IVUS |
Understanding the physics and types of available devices for intracoronary imaging and how the physics and materials effect imaging, including |
Topol: Chapter 42 Kern:Chapter 10 |
|
|
|
|
|
|
| Methods and types |
|
|
Alan Berger, M.D. |
V |
V |
|
|
|
| Interpretation |
Practical skills in interpreting IVUS images pre and post intervention, and knowledge of common artifacts and pitfalls |
|
Alan Berger, M.D. |
V |
V |
|
|
|
| Quantitative angiography |
Understanding of the images required for qualitative analysis and the methods of quantitative analysis, including common reporting parameters (MLD/ mCSA, ref D, loss index, and common graphical displays, etc) |
Topol: Chapter 39 |
|
V |
V |
|
|
|
| CT Angio/MR perfusion |
An understanding of the imaging methods, strengths and weaknesses, with respect to clinical use for assessment of coronary anatomy, myocardial blood flow and viability assessment |
|
John Lesser, M.D. |
|
V |
|
|
|
| Intracardiac ultrasound |
|
|
|
|
|
|
|
|
| Methods and types |
Knowledge of the basic physics and views using ICE |
|
|
V |
V |
V |
|
|
| Interpretation |
Practical ability to interpret cardiac anatomy using ICE, particularly with respect to assessment of septal defects, measurements for device closure and assessment of the left atrium and valves. |
|
|
V |
V |
V |
|
|
| Indications for PCI |
Knowledge of the ACC/HA guidelines for intervention, surgery and medical therapy for coronary syndromes, with emphasis on special populations (diabetics, the elderly, women, patients with renal failure, etc.) |
|
|
V |
V |
V |
|
|
| Stable coronary disease |
|
ACC/AHA guidelines |
Alan Berger, M.D. |
V |
V |
V |
|
|
| Non-STEMI |
|
ACC/AHA guidelines |
|
V |
V |
V |
|
|
| STEMI |
|
ACC/AHA guidelines |
|
V |
V |
V |
|
|
| Special groups |
|
ACC/AHA guidelines |
|
V |
V |
V |
|
|
| Pre-transplantation |
|
|
|
V |
V |
V |
|
|
| Pre non-cardiac surgery |
|
|
|
V |
V |
V |
|
|
| Diabetics |
|
|
|
V |
V |
V |
|
|
| Renal failure |
|
|
|
V |
V |
V |
|
|
| Elderly |
|
|
|
V |
V |
V |
|
|
| |
|
|
|
|
V |
V |
|
|
| Patient preparation for PCI |
|
|
|
|
V |
V |
|
|
| General |
|
Patient preparation hand-out |
|
|
V |
V |
|
|
| history/physical/labs |
|
|
|
V |
V |
V |
|
|
| consent process |
|
|
|
V |
V |
V |
|
|
| Special circumstances |
|
|
|
|
V |
V |
|
|
| renal failure |
|
|
|
V |
V |
V |
|
|
| diabetes |
|
|
|
V |
V |
V |
|
|
| coagulation abnormalities |
|
|
|
V |
V |
V |
|
|
| Technical Aspects of PCI |
|
|
|
|
|
|
|
|
| Vascular Access |
|
|
|
|
|
|
|
|
| femoral |
Advanced knowledge of and technical skills for femoral artery vascular access, prevention of complications, hemostasis incl closure) and treatment of complications |
|
Panetta |
|
V |
V |
|
|
| radial |
Advanced knowledge of and technical skills for radial and brachial artery access and management of complications |
|
Panetta |
|
V |
V |
|
|
| Specific methods and tools |
|
|
|
|
|
|
|
|
| Guidewires |
Understanding how guidewire construction translates to performance, and appropriate selection of guidewires for specific vessels |
|
7-16-04 |
V |
V |
V |
|
|
| Guide catheters |
Understanding how guide catheter construction and curves translate to performance, and appropriate selection of guide catheters for specific vessels and aortic dimensions |
Kern: Chapter 1 |
Ginete and Chou 7/9/2004 |
V |
V |
V |
|
|
| Balloon PCI |
Knowledge of balloon catheter material and construction, any how to select the appropriate balloon for specific vessels/lesions |
|
|
|
V |
V |
|
|
| balloon types/performance |
|
Kern: Chapter 1 |
Ginete and Chou 7/16/2004 |
V |
V |
V |
|
|
| selection and passage |
Technical skills in balloon passage, including guide catheter/balloon catheter interaction |
Kern: Chapter 1 |
|
V |
|
V |
|
|
| Stenting |
|
|
|
|
|
|
|
|
| Stent design |
Knowledge of stent types and materials, and how these affect clinically relevant properties (conformability, passage, radial strength, etc) |
Topol: Chapter 28 |
Ginete and Chou-7/23/2004 |
|
V |
V |
|
|
| Drug elution |
Knowledge of 1. drug elution methods (polymers, ceramics, bonding) and 2. pharmacology o drugs used to prevent restenosis and thrombosis. |
Topol: Chapter 30 Kern: Chapter 7 |
Lecture |
|
V |
V |
|
|
| Implantation method |
|
Topol: Chapter 27 Kern: Chapter 1 |
|
V |
V |
V |
|
|
| Atherectomy |
|
|
|
|
|
|
|
|
| Rotational |
1. Knowledge of device physics, construction and setup. 2. Understanding of appropriate patient selection, vessel selection and technical skills for use of the device 3. Knowledge of device complications and management |
Topol: Chapter 26 Kern: Chapter 6 |
Wilson Ginete, M.D. 7/30/2004 and Debate: Bilal Murad v Alan Berger |
V |
V |
V |
|
|
| Directional/Extraction |
1. Knowledge of device physics, construction and setup. 2. Understanding of appropriate patient selection, vessel selection and technical skills for use of the device 3. Knowledge of device complications and management |
Topol: Chapter 25 Kern: Chapter 6 |
|
V |
V |
V |
|
|
| Laser |
1. Knowledge of device physics, construction and setup. 2. Understanding of appropriate patient selection, vessel selection and technical skills for use of the device 3. Knowledge of device complications and management |
Topol: Chapter 31 |
|
|
V |
V |
|
|
| Distal protection devices |
1. Knowledge of device constructions, appropriate patient selection, and deployment methods. 2 Knowledge of clinical trial results and impact on clinical use |
Topol Chapter 12 |
Wendy Shear, M.D. |
V |
V |
V |
|
|
| Brachytherapy |
1. Knowledge of basic radiation physics and dosimetry of coronary brachytherapy (beta and Gamma) |
Topol: Chapter 33 Kern: Chapter 7 |
Wes Pedersen, M.D. |
V |
V |
|
|
|
| Special circumstances |
1. Knowledge of the impact of lesion/vessel characteristics on procedural strategy, complications and long-term outcome. 2. Ability to select the optimal therapy for each lesion |
Topol: Chapters 10, 15,17 and 18 Kern: Chapter 8 |
|
|
V |
|
|
|
| Vascular calcification |
|
7 |
|
V |
|
|
|
|
| Tortuosity |
|
7 |
|
V |
|
|
|
|
| Ostial stenosis |
|
7 |
|
V |
|
|
|
|
| Bifurcation lesions |
|
7 |
|
V |
|
|
|
|
| Thrombosis |
|
7 |
|
V |
|
|
|
|
| Aneurismal disease |
|
7 |
|
V |
|
|
|
|
| Chronic total occlusions |
|
7 |
|
|
|
|
|
|
| Restenotic lesions |
|
|
|
|
|
|
|
|
| Role of CAB surgery |
|
Topol: Chapter 21 |
Ken Liao, M.D. |
|
|
|
|
|
| Interventional approach |
|
Topol: Chapter 22 |
|
V |
|
|
|
|
| Vascular closure devices |
Detailed understanding of suture and procoagulant vascular closure devices, appropriate patient selection for each device and management of complications |
|
|
|
|
|
|
|
| Selection and use |
|
Topol: Chapter 37 |
R. Wilson, M.D. |
V |
|
|
|
|
| Clinical outcome |
|
Topol: Chapter 37 |
R. Wilson, M.D. |
V |
|
|
|
|
| Stable coronary disease intervention |
|
|
|
|
|
|
|
|
| Indications |
1. Knowledge of the factors that influence patient outcome with respect to revascularization. 2. Ability to properly select patients for revascularization, and to select the optimum approach3. Strategies that reduce complications |
|
|
|
V |
V |
|
|
| Symptomatic patients |
|
AHA/ACC guidelines |
|
V |
V |
V |
|
|
| Asymptomatic/high risk |
|
AHA/ACC guidelines |
|
V |
V |
V |
|
|
| Special patient groups |
|
AHA/ACC guidelines |
|
|
V |
V |
|
|
| Pre-transplantation |
|
|
|
V |
V |
V |
|
|
| Pre non-cardiac surgery |
|
|
|
V |
V |
V |
|
|
| Diabetics |
|
|
|
V |
V |
V |
|
|
| Renal failure |
|
|
|
V |
V |
V |
|
|
| Other non-atherosclerotic coronary disease |
|
AHA/ACC guidelines |
|
V |
V |
V |
|
|
| Kawasaki (MCLNS) |
|
|
|
|
V |
V |
|
|
| collagen vascular diseases |
|
|
|
|
V |
V |
|
|
| radiation arteriopathy |
|
|
|
|
V |
V |
|
|
| coronary transplant arteriopathy |
|
|
|
|
V |
V |
|
|
| |
|
|
|
|
|
|
|
|
| Acute coronary syndromes |
|
|
|
|
|
|
|
|
| Physiology of unstable angina and MI |
A detailed understanding of the pathology and physiology of acute coronary syndromes 2. Optimal imaging and physiological diagnostic methods for assessing ACS |
Topol Chapter 6 |
|
|
V |
|
|
|
| Coronary events |
|
|
|
|
V |
|
|
|
| plaque rupture and thombosis |
|
|
|
|
V |
|
|
|
| IVUS findings |
|
|
Berger: IVUS |
|
V |
V |
|
|
| Myocardial necrosis |
|
|
The Troubles part 1 |
|
V |
|
|
|
| embolization and microvascular injury |
|
|
|
|
V |
|
|
|
| myocyte necrosis, inflamation and healing |
|
|
|
|
V |
|
|
|
| |
|
|
|
|
V |
|
|
|
| Clinical course and complications |
Understanding of the clinical correlates of the ACS physiololgy and pathology and how they relate to outcome. |
Topol Chapter 12 |
Henry: Clinical trials |
|
V |
V |
|
|
| non-STEMI ACS |
|
|
|
V |
|
V |
|
|
| STEMI |
|
|
|
V |
|
V |
|
|
| Interventional treatment of non-STEMI |
|
|
|
|
|
V |
|
|
| Indications for intervention |
Optimal patient selection for intervention, including strategic decisions that affect case approach and long-term outcome |
AHA/ACC guidelines |
|
V |
|
V |
|
|
| Acute revasculariztion |
Ability to optimallyand safely plan and perform ACS revascularization |
|
|
V |
|
V |
|
|
| techniques to avoid embolization/slow flow |
|
|
|
V |
|
V |
|
|
| complete v incomplete revascularization |
|
|
Lecture |
V |
|
V |
|
|
| prophylactic circulatory support |
|
|
Das: Circulatory support |
V |
V |
V |
|
|
| Follow-up teatment |
Optimal post procedure care and institution of evidence based prevention regimens |
|
|
V |
V |
V |
|
|
| drug/prevention therapy |
|
|
|
V |
V |
V |
|
|
| Interventional treatment of acute MI |
Skills for optimal patient selection for interventional therapy, including strategic decisions that affect case approach, understanding of system issues to optimize timing of therapy and post MI therapy |
|
|
V |
V |
V |
|
|
| Indications and timing of intervention |
|
AHA/ACC guidelines |
|
V |
V |
V |
|
|
| timing/system performance |
|
|
|
V |
|
V |
|
|
| rescue and late reperfusion |
|
|
|
V |
|
V |
|
|
| |
|
|
|
|
|
V |
|
|
| Acute reperfusion |
Abiltity to rapidly manage and perform acute reavscuarization with PCI |
|
|
V |
|
V |
|
|
| anticoagulation |
|
|
|
V Level One program, UM cath call |
|
V |
|
|
| revacsularization methods |
|
|
|
V |
|
V |
|
|
| adjunctive salvage therapy |
|
|
|
V |
|
V |
|
|
| circulatory support |
|
|
|
V |
|
V |
|
|
| role of thrmbolytic drugs |
|
|
|
V |
|
V |
|
|
| Follow-up teatment |
|
|
|
V |
|
V |
|
|
| drug/prevention therapy |
|
|
|
V |
|
V |
|
|
| ICD indications |
|
|
|
V |
|
V |
|
|
| |
|
|
|
|
|
|
|
|
| Bypass graft intervention |
|
|
|
|
|
|
|
|
| Pathology of graft disease |
Understanding of the interplay between the pathology of bypass graft disease and the therapeutic approach |
|
Wendy Shear, M.D. |
|
V |
|
|
|
| early (<1 year) |
|
|
|
V |
V |
|
|
|
| late (>1 year) |
|
|
|
V |
V |
|
|
|
| Methods of bypass graft intervention |
Ability to plan and perform interventions in bypass grafts, with attention to embolism protection and no-reflow. |
Topol: Chapter 16 |
Wendy Shear, M.D. |
|
|
V |
|
|
| guide selection |
|
|
|
V |
|
V |
|
|
| ostial lesions |
|
|
|
V |
|
V |
|
|
| body lesions |
|
|
|
V |
|
V |
|
|
| coronary insertion lesions |
|
|
|
V |
|
V |
|
|
| embolism protection devices/methods |
|
|
|
V |
|
V |
|
|
| anticoagulation |
|
|
|
V |
|
V |
|
|
| Complications of bypass graft PCI |
|
Topol: Chapter 16 |
Wendy Shear, M.D. |
V |
|
V |
|
|
| slow/no flow |
|
|
R. Wilson, M.D. |
V |
|
V |
|
|
| perforation |
|
|
|
V |
|
V |
|
|
| Follow-up treatment/drugs |
|
Topol: Chapter 16 |
Wendy Shear, M.D. |
V |
|
V |
|
|
| |
|
|
|
|
|
V |
|
|
| Complications of PCI |
|
|
|
|
|
|
|
|
| Acute complications, treatment and prevention |
Knowledge of acute complications, including: 1: Incidence of individual complications, 2: conditions making each complication more likely, 3: appropriate methods to reduce the liklihood of complications, 4: optimal management of complications |
|
|
|
V |
V |
|
|
| Dissection |
|
|
|
|
V |
|
|
|
| Coronary |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Aortic |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Peripheral vascular |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Vasospasm |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Thrombosis |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Embolization |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Slow/No flow |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Myocardial infarction |
|
|
|
|
V |
|
|
|
| Mechanisms and prevention |
|
|
|
V |
V |
|
|
|
| Treatment |
|
|
|
V |
V |
|
|
|
| Stroke |
|
|
|
V |
V |
|
|
|
| Peripheral vascular |
|
|
The Troubles (part 1) |
|
V |
|
|
|
| Hematoma/bleeding |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Pseudoaneurysm/AV fistuala |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Embolization (non-renal) |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Renal failure |
|
|
The Troubles (part 1) |
|
V |
|
|
|
| contrast induced |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| embolization/other |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Stroke |
|
|
The Troubles (part 1) |
V |
V |
|
|
|
| Predictors of poor outcome |
|
|
Harbingers of failure |
V |
V |
|
|
|
| Late complications |
|
|
|
|
V |
|
|
|
| Restenosis |
Understaing of the pathophysiology and risk factors for restenosis |
|
|
|
V |
|
|
|
| pathophysiology |
|
|
Pathobiology of restenosis |
|
V |
|
|
|
| clinical predictors |
|
|
|
V |
V |
V |
|
|
| treatment |
Ability to tailor the type and location of restenosis to the best therapy |
|
|
V |
V |
V |
|
|
| Progressive disease |
1. knowledge of the impact of residual disease on early and late outcome, 2. ability to develop a revascularization strategy based on the patient's underlying conditions, coronary anatomy, and predicted outcome (evidence based). |
|
|
|
V |
V |
|
|
| complete vs incomplete revascularization |
|
|
Complete v incomplete revascularization |
V |
V |
V |
|
|
| predictors of late MI or death |
|
|
Harbingers of failure |
|
V |
|
|
|
| |
|
|
|
|
|
|
|
|
| Interventional valvular therapy |
|
|
|
|
|
|
|
|
| Indications for intervention of stenotic valve disease |
Knowedge of the natural disease course and optimal timimng for intervention of valvular heart disease |
|
Pedersen: Aortic valvuloplasty |
|
V |
|
|
|
| aortic |
|
|
Pedersen: Aortic valvuloplasty |
Perform 2 aortic valvuloplasties |
V |
|
|
|
| mitral |
|
|
Baran: Mitral and pulmonary valvuoplasty |
Perform 2 mitral valvuloplasties |
V |
|
|
|
| pulmonary |
|
|
Baran: Mitral, TC and pulmonary valvuoplasty |
Perform procedures as available |
V |
|
|
|
| tricuspid |
|
|
Baran: Mitral, TC and pulmonary valvuoplasty |
Perform procedures as available |
V |
|
|
|
| prosthetic valve |
|
|
Baran: Mitral, TC and pulmonary valvuoplasty |
Perform procedures as available |
V |
|
|
|
| Techniques and complications |
Clinical experience performing a limited number of aortic and mitral valve dilations, with a knowledge of procedural approach and common complications |
|
Lectures as above |
Perform procedures as available (>5 Ao, >2 mitral) |
V |
V |
|
|
| aortic |
|
|
|
>5 |
|
V |
|
|
| mitral |
|
|
|
>2 |
|
V |
|
|
| pulmonary |
|
|
|
V |
|
V |
|
|
| tricuspid |
|
|
|
V |
|
V |
|
|
| prosthetic valve |
|
|
|
V |
|
|
|
|
| |
|
|
|
|
|
V |
|
|
| Congenital heart disease intervention |
|
|
|
|
|
|
|
|
| ASD/PFO closure |
Knowledge of indications for ASD and PFO closure and the ability to close common defects |
Kern: Chapter 15 Topol: Chapter 45 |
Gladwin Das, M.D. |
Perform >5 closures |
V |
|
|
|
| Indications for treatment |
|
|
|
|
V |
|
|
|
| Interventional techniques and device selsction |
1. Ability to use TEE and ICE to evaluate septal defects and select appropiate patients, select propoerly size devices, and evaluate results 2. Performance of 15 closures |
|
|
Perform >5 closures |
|
V |
|
|
| Follow-up treatment |
Knowledge of follow-up complications, follow-up imaging, antiplatelt therapy and BE prophylaxis |
|
|
Perform >5 closures with follow-up |
V |
|
|
|
| VSD closure |
An introduction to experimental devices used for VSD closure and factors that influence patient selection |
|
John Bass, M.D. |
|
V |
|
|
|
| Indications for treatment |
|
|
|
|
|
|
|
|
| Surgical v experimental device therapy |
|
|
|
|
|
|
|
|
| Interventional techniques and device selsction |
|
|
|
|
|
|
|
|
| Follow-up treatment |
|
|
|
|
|
|
|
|
| Hypertrophic cardiomyopathy |
1. Ability to appropriately dignose and select pateinst for ASA, 2. Knowledge of the procedural methods, including imaging interpretation and assess ment of resluts/stopping points 3. Understanding of incidence and treatment of complications of ASA |
Kern: Chapter 14 Topol: Chapter 47 |
R. Wilson, M.D. Nick Burke, M.D. |
|
|
|
|
|
| Indications for treatment |
|
|
|
|
|
|
|
|
| Interventional methods |
|
|
|
|
|
|
|
|
| Complications and management |
|
|
|
|
|
|
|
|
| Follow-up treatment |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| Advanced/experimental therapies |
|
|
|
|
|
|
|
|
| Stem cell therapy for acute MI and CHF |
A basic understanding of stem cell therapy and approaches to treatment of acute MI and heart failure |
Topol: Chapter 38 |
Tim Henry, M.D. |
|
V |
|
|
|
| Angio and vascular genesis |
A basic understanding of approaches to angiogenic therapy, patient selection for trials, trial design, and clinical results of on-going trials |
|
Tim Henry, M.D. |
|
V |
|
|
|
| Growth factors |
|
|
|
|
|
|
|
|
| Gene therapy |
|
|
|
|
|
|
|
|
| PMR |
|
|
|
|
|
|
|
|
| System management and quality assessment/improvement |
|
|
|
|
|
|
|
|
| Cath lab QI management |
Tools for assessing and improving cath lab quality |
|
Wilson: Cath lab QA systems and management |
Cath lab M&M |
V |
|
|
|
| Multidisciplinary approach |
Effective team development and functioning |
|
|
Film@5 multidisciplinary team |
|
V |
V |
|
| Professionalism and communication |
|
|
|
|
|
|
|
|
| Professional ethics |
|
|
|
Clinical role modeling |
|
V |
|
|
| Effective communication with referring physicians |
Develop tools for effective communication with referring physicians and healthcare team |
|
|
Clinical communication with housestaff |
|
V |
|
|
| Teaching development |
Develop skills for effective presentations |
|
|
Journal club presentations |
|
V |
|
|
| Effective communication with cath lab team |
|
|
|
Clinical communication with team/360 eval feedback |
|
|
V |
|
| Practice based learning |
|
|
|
|
|
|
|
|
| Complication management and avoidance |
|
|
|
Clinical mentoring/ M&M conference |
|
V |
|
|
| Clinical decision making |
|
|
|
Clinical case mentoring/ Film@5 |
|
V |
V |
|